Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ILOPERIDONE vs ABILIFY ASIMTUFII
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
Acute treatment of schizophrenia in adults
Schizophrenia,Maintenance monotherapy treatment of bipolar I disorder
1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
Terminal elimination half-life 18 hours in extensive CYP2D6 metabolizers, 33 hours in poor metabolizers; clinical context: steady-state reached in ~5-7 days.
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Primarily metabolized by CYP3A4 and CYP2D6 to two major metabolites (P88 and P95); also a minor substrate of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2E1.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole is formed primarily by CYP3A4 and CYP2D6; exhibits significant interindividual variability due to CYP2D6 polymorphism.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; approximately 7% excreted unchanged in urine and 18% in feces; total renal elimination of metabolites ~25%, fecal ~60%.
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
~95% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
>99% bound to serum albumin.
Vd/F ~20 L/kg (oral); large distribution indicates extensive tissue binding.
4.9 L/kg, indicating extensive extravascular distribution.
Oral bioavailability is approximately 96% relative to oral solution; food does not significantly affect absorption.
Intramuscular: 100% (as a depot suspension).
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce by 75%; GFR <15 m L/min: not recommended
No dosage adjustment required for patients with renal impairment (Cr Cl ≥15 m L/min). Insufficient data for patients with end-stage renal disease (Cr Cl <15 m L/min).
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: contraindicated
No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh class A or B). Use with caution in severe hepatic impairment (Child-Pugh class C) as experience is limited.
Not established; safety and efficacy not evaluated in patients <18 years
Not approved for use in pediatric patients. Safety and efficacy have not been established.
Initiate at 1 mg twice daily; increase slowly; monitor for orthostatic hypotension and anticholinergic effects
Use with caution due to increased sensitivity to orthostatic hypotension and sedative effects. Consider lower starting doses (300 mg orally equivalent) but no specific dose adjustment for the injectable form is recommended.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Iloperidone is not approved for the treatment of patients with dementia-related psychosis.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis,QT interval prolongation (particularly with concomitant use of drugs that prolong QT or in patients with risk factors),Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Orthostatic hypotension (particularly during initial dose titration),Seizures,Leukopenia, neutropenia, and agranulocytosis,Body temperature regulation impairment,Dysphagia,Cognitive and motor impairment
Increased mortality in elderly patients with dementia-related psychosis; cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome (NMS); tardive dyskinesia; metabolic changes (hyperglycemia/diabetes mellitus, dyslipidemia, weight gain); pathological gambling and other compulsive behaviors; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; potential for additive effects with alcohol or CNS depressants; injection site reactions; risk of extrapyramidal symptoms; suicidal thoughts/behaviors.
Known hypersensitivity to iloperidone or any component of the formulation
Known hypersensitivity to aripiprazole or any component of the formulation; concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin)
Grapefruit juice may inhibit CYP3A4 metabolism, increasing iloperidone concentrations; avoid concurrent use. High-fat meals may slightly reduce absorption; take consistency.
Avoid grapefruit juice and grapefruit products as they may increase aripiprazole levels. Alcohol should be limited or avoided due to additive CNS depression and increased risk of sedation.
First trimester: Limited human data; animal studies show increased fetal resorption and developmental delays at doses similar to human exposure. Second and third trimesters: May cause extrapyramidal symptoms and/or withdrawal symptoms in neonates (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Advise use only if benefit outweighs risk.
Iloperidone is excreted into human milk. M/P ratio: unknown. Use caution; consider benefits of breastfeeding vs. risk of infant exposure. Monitor infant for sedation, poor feeding, extrapyramidal symptoms.
Excreted in human milk; limited data. M/P ratio not established. Decision to discontinue nursing or drug based on importance of drug to mother. Use caution.
No specific dose adjustment guidelines exist for pregnancy. Due to increased plasma volume and renal clearance during pregnancy, consider therapeutic drug monitoring to maintain efficacy. Lower doses may be needed if adverse effects occur; use lowest effective dose.
No recommended dose adjustments in pregnancy; consider pharmacokinetic changes (e.g., increased clearance) may require titration, but evidence lacking.
Iloperidone is an atypical antipsychotic with a low propensity for extrapyramidal symptoms but significant QTc prolongation risk; obtain baseline ECG and monitor electrolytes. Titrate slowly to mitigate orthostatic hypotension due to alpha-1 blockade. Dosing adjustments required in CYP2D6 poor metabolizers (reduce dose by 50%). Avoid concomitant use with QT-prolonging drugs or CYP3A4/2D6 inhibitors/inducers.
ABILIFY ASIMTUFII (aripiprazole) is a long-acting injectable suspension for intramuscular use. Administer only by a healthcare professional. Observe patient for 2 hours post-injection due to risk of post-injection delirium/sedation syndrome. Requires 3 consecutive daily doses of oral aripiprazole (10-20 mg) before initiation to confirm tolerability. Dosing: 441 mg IM monthly (equates to 400 mg aripiprazole). Do not substitute with other aripiprazole formulations on a mg-per-mg basis. Contraindicated in patients with known hypersensitivity to aripiprazole.
Do not drive or operate machinery until you know how iloperidone affects you, as it may cause dizziness, drowsiness, or blurred vision.,Rise slowly from sitting or lying positions to prevent falls due to low blood pressure.,Report any fast, pounding, or irregular heartbeat, especially with lightheadedness or fainting.,Avoid alcohol and grapefruit juice as they may increase side effects or drug levels.,If you experience muscle stiffness, fever, confusion, or sweating, seek emergency help immediately, as these may be signs of neuroleptic malignant syndrome.
This medication is given as an injection once a month by your healthcare provider.,Do not try to inject yourself; it must be given by a healthcare professional.,After each injection, you will need to stay at the doctor's office or clinic for at least 2 hours to be monitored for any serious side effects.,You will need to take oral aripiprazole for 3 days before your first injection to see if you can tolerate the medication.,Common side effects include headache, insomnia, nausea, and injection site pain.,Seek emergency care if you have allergic reaction (hives, difficulty breathing, swelling), uncontrolled muscle movements, or thoughts of suicide.,Avoid alcohol and grapefruit juice while on this medication.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment without consulting your doctor.
"Iloperidone, an atypical antipsychotic, prolongs the QT interval by blocking cardiac potassium channels (hERG), while Methsuximide, a succinimide anticonvulsant, may also prolong the QT interval via similar mechanisms. Co-administration can lead to additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This is particularly dangerous in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"The interaction between iloperidone and aprepitant results from iloperidone's moderate inhibition of CYP3A4, the primary enzyme responsible for aprepitant metabolism. This inhibition can lead to increased aprepitant plasma concentrations, potentially enhancing its antiemetic effects and risk of adverse events such as hiccups, constipation, and headache. Clinical significance is greater during the 3-day aprepitant regimen for chemotherapy-induced nausea and vomiting, as elevated levels may prolong its therapeutic and side effect profile."
"Concomitant administration of propoxycaine, an ester-type local anesthetic, and iloperidone, an atypical antipsychotic, may increase the risk of QT interval prolongation and torsade de pointes due to additive effects on cardiac repolarization. Propoxycaine can also elevate catecholamine levels, potentially enhancing iloperidone's effects on blood pressure and heart rate. These interactions could manifest as palpitations, syncope, or life-threatening arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ILOPERIDONE vs ABILIFY ASIMTUFII, answered by our medical review team.
ILOPERIDONE is a Atypical Antipsychotic that works by Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.. ABILIFY ASIMTUFII is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ILOPERIDONE and ABILIFY ASIMTUFII depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ILOPERIDONE is: 1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day. The standard adult dose of ABILIFY ASIMTUFII is: Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ILOPERIDONE and ABILIFY ASIMTUFII in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ILOPERIDONE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and developmental delays at doses similar to human exposure. Second and third trimesters: May ca. ABILIFY ASIMTUFII is classified as Category C. Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Adv. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.